Company updateBusinessLine
Lupin launches biosimilar Ranibizumab through Sandoz in Europe
Positive+172 sources
GreyOak summary
Lupin Ltd launched its biosimilar Ranibizumab, branded as Ranluspec, across Europe excluding Germany through its commercial partner Sandoz. The European Commission approved the product in vial and pre-filled syringe presentations for treating various retinal diseases. This launch marks a milestone in expanding access to quality biologic treatment options for patients with neovascular age-related macular degeneration and other conditions.
What it affects
- LupinLUPINPositive +17
Launched biosimilar Ranibizumab in Europe via Sandoz.Rolling sentiment Neutral -8
Source
Read the original at BusinessLineMore Lupin news
- Prabhudas Lilladher maintains Accumulate rating on Lupin with target of Rs 2250Moneycontrol · Company update ·